<DOC>
	<DOCNO>NCT02353247</DOCNO>
	<brief_summary>The overall objective study confirm oral progesterone effective way manage bothersome bleeding ; thus increase rate continuation etonogestrel contraceptive implant adolescent .</brief_summary>
	<brief_title>Use Norethindrone Acetate Management Bleeding Associated With Etonogestrel Contraceptive Implant</brief_title>
	<detailed_description>The investigator conduct prospective study adolescent use etonogestrel contraceptive implant . Participants recruit Kosair Children 's Hospital Gynecology Specialists practice Louisville , Kentucky . This practice provide care diverse population female , wide range socioeconomic status , age birth 25 year . All patient present choose implant place offer participation . All enrollment voluntary . Participants receive compensation participation . After obtain informed consent assent , participant provide baseline demographic information , include : age , race/ethnicity , zip code residence , health insurance provider , number current past partner , use prior contraceptive method , concomitant condom use , sexually transmitted infection history , smoke status , weight height . The date etonogestrel implant insertion confirm . All patient use etonogestrel contraceptive implant receive daily SMS text even via Qualtrics SMS program ask respond bleeding pattern day . The investigator record responses accord World Health Organization definition bleeding : ( ) bleeding day , ( b ) spotting day , ( c ) bleeding -- ‐ free day [ see Table I WHO bleed definition ] . At initial follow -- ‐up visit 3 month Nexplanon insertion , investigator identify report `` bothersome '' bleeding pattern . For purpose study , `` bothersome '' bleeding define prolonged and/or frequent bleeding , characterize World Health Organization -- ‐recommended definition bleed . The definition list Table I . Bleeding day Any day vaginal discharge contain blood require 1 sanitary pad tampon per day Spotting day Any day vaginal discharge contain blood require one sanitary pad tampon per day Bleeding -- ‐free day A day neither bleeding spotting report Bleeding -- ‐ spotting episode One consecutive day bleed spotting enter diary , bound bleeding -- ‐free day Amenorrhea No bleed spot day throughout 90 -- ‐day reference period Infrequent bleeding Less three bleeding -- ‐spotting episode 90 -- ‐day reference period , exclude amenorrhea Normal frequency Three five bleeding -- ‐spotting episode 90 -- ‐day reference period Frequent bleed More five bleeding -- ‐spotting episode 90 -- ‐day reference period Prolonged bleed Any bleeding -- ‐spotting episode ( uninterrupted ) last 14 day 90 -- ‐day reference period Table I : WHO bleed description pattern Norethindrone acetate ( aygestin ) use manage bothersome bleeding . Patients prescribe aygestin 5 mg mouth twice daily one month , follow aygestin 5 mg mouth daily two month . Medication discontinue . Patients evaluate office three month medication initiation , six month medication initiation . If patient unable take norethindrone acetate ( aygestin ) due medical contraindication cost , receive medroxyprogesterone acetate ( provera ) 10 mg daily alternate oral progesterone . Figure 1 highlight study design . Contraceptive implant insert &amp; enrollment study Bleeding pattern record via SMS text x 3 month Office visit Normal bleeding pattern Bothersome bleeding pattern Continue record bleeding pattern Aygestin 5 mg PO BID x 1 month* Continue record bleeding pattern Aygestin 5 mg PO daily x 2 month Continue record bleeding pattern No mediation x 3 month Office visit Office visit *Or provera 10 mg PO daily x 3 month Figure 1 : Study design During aygestin administration , patient receive daily SMS text even via Qualtrics SMS program ask respond bleeding pattern day . The investigator record responses accord World Health Organization definition bleeding : ( ) bleeding day , ( b ) spotting day , ( c ) bleeding -- ‐ free day . Patients report bothersome bleed initial 90 day continue record bleeding via SMS texts next 6 month serve control group ( normal bleed group ) . All complete demographic data collection form electronic menstrual calendar keep database , de -- ‐identified , store password -- ‐ protect computer . Study size convenience sample . Based current rate etonogestrel implant insertion practice , anticipate 30 participant recruit six -- ‐month period time . Data Collection Analysis All patient meet inclusion criterion enroll study send text message daily 90 day ( 3 month ) . The daily message prompt participant indicate bleeding level day . This single question 4 option : 1 . Bleeding Day 2 . Spotting Day 3 . Bleeding Free Day 4 . Prefer answer today . On day 90 , descriptive tally responses do . Using SPSS v20 , algorithm count number bleeding day , spot day , bleed free day prefer answer ( PNA ) day ; data record participant contain four count variable ( bleed , spot , free , PNA ) . Secondly , algorithm identify tally -according WHO guideline Table 1 -- ‐ bleeding -- ‐spotting episode ( BSE ) , amenorrhea ( AM ) , infrequent bleeding ( IF ) , normal frequency bleeding ( NF ) , frequent bleeding ( FB ) , prolong bleeding ( PB ) . Participants least single episode FB PB assign label `` bothersome bleeding '' . Those without single episode FB PB label `` normal bleeding '' . Participants Bothersome Bleeding group offer aygestin control bothersome bleeding . Participants Normal Bleeding group continue , additional medication . Following principle intent -- ‐to -- ‐treat , data Bothersome Bleeding group assign aygestin group , despite take . During first month , participant Bothersome Bleeding group take one 5 mg tablet aygestin twice daily ( morning evening ) . After 30 day , dose aygestin halve , one 5 mg tablet take daily . Sixty day later , Bothersome Bleeding group discontinue aygestin . Ninety day later , normal group Bothersome Bleeding group re-evaluated . Data Analysis A descriptive table use sort participant Normal Bleeding Bothersome Bleeding . Non -- ‐parametric parametric statistic use compare demographic two group . A dose -- ‐response curve cover six month plot Bothersome Bleeding group visually reveal impact one month 10 mg aygestin vs. two month 5 mg aygestin vs. three month 0 mg aygestin . Plotted curve group average daily bleed value ( 1 bleeding , .5 spotting , 0 bleeding ) . A second -- ‐dose curve add X -- ‐Y plot six month data Normal Bleeding group . Repeated Measure Multivariate Analysis Variance ( RM -- ‐ANOVA ) Between -- ‐ Subjects variable include , conduct ( assume sufficient data available - e.g. , low PNA rate ) compare first 30 day average bleed value , 90 day bleeding average , 180 day bleed average two group . Planned post -- ‐hoc comparison evaluate change control group intervention group three time point . Additional analysis may also include regression analysis assess predictive factor relate response aygestin .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<criteria>Inclusion criterion include post‐menarchal female present Kosair Children 's Hospital Gynecologic Specialist practice , desire use etonogestrel contraceptive implant access mobile phone device .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>